Tags

Type your tag names separated by a space and hit enter

Holotranscobalamin and methylmalonic acid as prognostic markers following an acute myocardial infarction.
Eur J Clin Nutr. 2008 Mar; 62(3):411-8.EJ

Abstract

OBJECTIVE

To evaluate whether low levels of holotranscobalamin (holoTC) or elevated levels of methylmalonic acid (MMA), both indicators of vitamin B(12) deficiency, might predispose to new cardiovascular events following an acute myocardial infarction (MI).

DESIGN

A prospective prognostic study.

SETTING

One hospital center in Stavanger, Norway.

SUBJECTS

A total of 300 patients admitted with an acute MI.

METHODS

Registration of new TnT positive coronary events (defined as TnT>0.05 microg/l and a typical MI pattern) and/or cardiac death during a median follow-up time of 45 months.

RESULTS

We compared the recurrence of events in the lowest quartile of holoTC (Q1<73.9 pmol/l) to the event rate above the 25% percentile (Q2-4). For methylmalonic acid (MMA) the same comparison was carried out for the upper quartile (Q4 > or =0.24 micromol/l) as compared with the event rate below the 75% percentile (Q1-3). After 18 and 45 months of follow-up, the odds ratio (OR) for Q1 vs Q2-4 for holoTC was 1.15 (95% confidence interval (CI) 0.91-1.46, P=0.25) and 1.05 (95% CI 0.86-1.29, P=0.64), respectively. For MMA the OR for Q4 vs Q1-3 was 0.95 (95% CI 0.76-1.19, P=0.67) after 18 months and 1.01 (95% CI 0.83-1.23, P=0.90) after 45 months.

CONCLUSION

This study showed no increased risk of future cardiovascular events associated with low levels of holoTC or high levels of MMA following an acute MI.

Links

Aggregator Full Text

Authors+Show Affiliations

Aarsetøy H
Department of Medicine, Stavanger University Hospital, Stavanger, Norway. aahi@sus.no
Valente E
No affiliation info available
Reine A
No affiliation info available
Mansoor MA
No affiliation info available
Grundt H
No affiliation info available
Nilsen DW
No affiliation info available

MeSH

Acute DiseaseAgedAged, 80 and overBiomarkersFemaleFollow-Up StudiesHomocysteineHumansMaleMethylmalonic AcidMyocardial InfarctionOdds RatioPrognosisRecurrenceTime FactorsTranscobalaminsVitamin B 12Vitamin B 12 Deficiency

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17342163

Citation

Aarsetøy, H, et al. "Holotranscobalamin and Methylmalonic Acid as Prognostic Markers Following an Acute Myocardial Infarction." European Journal of Clinical Nutrition, vol. 62, no. 3, 2008, pp. 411-8.
Aarsetøy H, Valente E, Reine A, et al. Holotranscobalamin and methylmalonic acid as prognostic markers following an acute myocardial infarction. Eur J Clin Nutr. 2008;62(3):411-8.
Aarsetøy, H., Valente, E., Reine, A., Mansoor, M. A., Grundt, H., & Nilsen, D. W. (2008). Holotranscobalamin and methylmalonic acid as prognostic markers following an acute myocardial infarction. European Journal of Clinical Nutrition, 62(3), 411-8.
Aarsetøy H, et al. Holotranscobalamin and Methylmalonic Acid as Prognostic Markers Following an Acute Myocardial Infarction. Eur J Clin Nutr. 2008;62(3):411-8. PubMed PMID: 17342163.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Holotranscobalamin and methylmalonic acid as prognostic markers following an acute myocardial infarction. AU - Aarsetøy,H, AU - Valente,E, AU - Reine,A, AU - Mansoor,M A, AU - Grundt,H, AU - Nilsen,D W T, Y1 - 2007/03/07/ PY - 2007/3/8/pubmed PY - 2008/7/2/medline PY - 2007/3/8/entrez SP - 411 EP - 8 JF - European journal of clinical nutrition JO - Eur J Clin Nutr VL - 62 IS - 3 N2 - OBJECTIVE: To evaluate whether low levels of holotranscobalamin (holoTC) or elevated levels of methylmalonic acid (MMA), both indicators of vitamin B(12) deficiency, might predispose to new cardiovascular events following an acute myocardial infarction (MI). DESIGN: A prospective prognostic study. SETTING: One hospital center in Stavanger, Norway. SUBJECTS: A total of 300 patients admitted with an acute MI. METHODS: Registration of new TnT positive coronary events (defined as TnT>0.05 microg/l and a typical MI pattern) and/or cardiac death during a median follow-up time of 45 months. RESULTS: We compared the recurrence of events in the lowest quartile of holoTC (Q1<73.9 pmol/l) to the event rate above the 25% percentile (Q2-4). For methylmalonic acid (MMA) the same comparison was carried out for the upper quartile (Q4 > or =0.24 micromol/l) as compared with the event rate below the 75% percentile (Q1-3). After 18 and 45 months of follow-up, the odds ratio (OR) for Q1 vs Q2-4 for holoTC was 1.15 (95% confidence interval (CI) 0.91-1.46, P=0.25) and 1.05 (95% CI 0.86-1.29, P=0.64), respectively. For MMA the OR for Q4 vs Q1-3 was 0.95 (95% CI 0.76-1.19, P=0.67) after 18 months and 1.01 (95% CI 0.83-1.23, P=0.90) after 45 months. CONCLUSION: This study showed no increased risk of future cardiovascular events associated with low levels of holoTC or high levels of MMA following an acute MI. SN - 0954-3007 UR - https://www.unboundmedicine.com/medline/citation/17342163/Holotranscobalamin_and_methylmalonic_acid_as_prognostic_markers_following_an_acute_myocardial_infarction_ L2 - https://doi.org/10.1038/sj.ejcn.1602701 DB - PRIME DP - Unbound Medicine ER -